Quick Answer
CATALYST PHARMACEUTICALS, INC. reported Cash and Equivalents of $709.17 million for fiscal year 2025.
CATALYST PHARMACEUTICALS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $709.17M | +37.0% |
| 2024 | $517.55M | +276.0% |
| 2023 | $137.64M | -53.9% |
| 2022 | $298.39M | +74.0% |
| 2021 | $171.44M | +31.6% |
| 2020 | $130.24M | +45.5% |
| 2019 | $89.51M | +440.6% |
| 2018 | $16.56M | -71.2% |
| 2017 | $57.50M | +313.9% |
| 2016 | $13.89M | -50.8% |
| 2015 | $28.24M | +210.4% |
| 2014 | $9.10M | +310.5% |
| 2013 | $2.22M | +57.2% |
| 2012 | $1.41M | -76.6% |
| 2011 | $6.03M | +10.1% |
| 2010 | $5.48M | -29.6% |
| 2009 | $7.78M | -33.9% |
| 2008 | $11.77M | +11666.6% |
| 2001 | $100.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $689.89M | +56.0% | +5.7% |
| June 30, 2025 | $652.80M | +73.8% | +12.4% |
| March 31, 2025 | $580.66M | +87.1% | +12.2% |
| December 31, 2024 | $517.55M | +276.0% | +17.0% |
| September 30, 2024 | $442.33M | +265.7% | +17.7% |
| June 30, 2024 | $375.69M | +110.1% | +21.0% |
| March 31, 2024 | $310.41M | +109.4% | +125.5% |
| December 31, 2023 | $137.64M | -53.9% | +13.8% |
- CATALYST PHARMACEUTICALS, INC. showed an increase of +37.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2001–2025 period, CATALYST PHARMACEUTICALS, INC.’s cash and equivalents has grown by 709071.0% (from $100.0 thousand to $709.17 million).
- The most recent figure is from CATALYST PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: